Although some studies have found no significant association between β2AR medications and PD risk [3,4], others have suggested that the chronic use of β2AR blockers has neuroprotective effects [5] and reduces the risk of PD [6,7,8]. The gene discussed is ADRB2; the disease is Parkinson disease.